TOMDF Pengajuan SEC - Todos Medical Ltd.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1645260

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Todos Medical Ltd.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

July 17, 2023	15-12G	FORM 15 OMB APPROVAL UNITED STATES OMB Number: 3235-0167 SECURITIES AND EXCHANGE COMMISSION Expires: July 31, 2024 Washington, D.
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 000-56026 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 000-56026 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Todos Medical Ltd. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Todos Medical Ltd.
March 31, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SA
March 31, 2023	EX-10.1	Third Amendment to Revolving Line of Credit Agreement entered into as of March 24 2023 by and between Todos Medical Ltd. a corporation organized under the laws of Israel, Corona Diagnostics LLC, a limited liability company organized under the laws of the State of Nevada, Provista Diagnostics Inc. a corporation organized under the laws of the State of Delaware, Todos Medical USA, Inc., a corporation organized under the laws of the State of Nevada, and Breakthrough Diagnostics, Inc., a corporation organized under the laws of the State of Nevada (the “Existing Borrowers”), and Todos Botanicals LLC, a limited liability company organized under the laws of the State of Nevada (the “New Borrower” and together with the Existing Borrowers, the “Borrower”), and Testing 123 LLC, a limited liability company organized under the laws of the State of Delaware (the “Lender”). Exhibit 10.1
March 15, 2023	SC 13D/A	TOMDF / Todos Medical Ltd / Strategic Investment Holdings, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) * Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) Strategic Investment Holdings, LLC 875 Carretera 693, Suite 201 Dorado, PR 00646 Tel: (787) 626-6500 (Name/Address/
February 17, 2023	SC 13D	TOMDF / Todos Med Ltd (Israel) / Strategic Investment Holdings, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) Strategic Investment Holdings, LLC 875 Carretera 693, Suite 201 Dorado, PR 00646 Tel: (787) 626-6500 (Name/Address/Tel
November 14, 2022	EX-10.64	Secured Promissory Note dated July 19, 2021, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.64
November 14, 2022	EX-10.66	Loan Agreement dated June 15, 2022, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.66
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 For the three months ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
November 14, 2022	EX-10.62	Secured Convertible Note entered into as of May 20, 2022, between the Company and Leviston Resources, LLC Exhibit 10.62
November 14, 2022	EX-10.63	Secured Loan Agreement dated July 19, 2021, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.63
November 14, 2022	EX-10.65	Amended and Restated Secured Convertible Promissory Note dated February 18, 2022, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.65
September 30, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Todos Medical Ltd.
September 29, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Todos Medical Ltd.
September 29, 2022	EX-10.1	Contract Manufacturing and Packaging Agreement, dated September 19, 2022, by and between Sky-Raider, LLC Nerd Hemp and Nerd brands % Legal Ease, and Todos Botanicals Inc. Exhibit 10.1
September 13, 2022	8-K/A	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO.
September 13, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Todos Medical Ltd.
September 13, 2022	EX-10.1	Commercial Lease Agreement dated August 30, 2022, by and between Industrial Property LLC and Todos Medical USA, Inc., (filed as Exhibit 10.1 to the Company’s report on Form 8-K/A on September 12, 2022). Exhibit 10.1 N o r t h T e x a s C o m m e r c i a l A s s o c i a t i o n o f R e a l t o r s ? C O M M E R C I A L L E A S E A G R E E M E N T between Industrial Property LLC (Landlord) and Todos Medical U.S.A. (Tenant) TABLE OF CONTENTS Article 1. Defined Terms 2 2. Lease and Term 8 3. Rent and Security Deposit 9 4. Taxes 10 5. Insurance and Indemnity 11 6. Use of Premises 12 7. Property Condit
September 13, 2022	EX-10.2	Conversion and Lock-up Agreement, dated August 31, 2022, by and between Todos Medical Ltd. and Leviston Resources LLC. Exhibit 10.2 CONVERSION AND LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (the ?Agreement?) is made and entered into as of the 31st day of August, 2022 between Todos Medical, Ltd., an Israeli corporation (the ?Company?) and Leviston Resources,LLC (the ?Holder?), holder of the Convertible Promissory Notes (each being a ?Note? and collectively the ?Notes?), or Common Stock Purchase Warrants (the ?Warrant
September 13, 2022	EX-10.1	Extension of Time Under Share Purchase Agreement, dated September 7, 2022, by and among 3CL Sciences, Ltd., an Israeli private company (“3CL”), Todos Medical Ltd., an Israeli public company (“Todos”), and NLC Pharma Ltd., an Israeli private company (“NLC”). Exhibit 10.1
September 1, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Todos Medical Ltd.
September 1, 2022	EX-10.1	Lease Agreement, dated August 30,2022, by and between Todos Medical USA, Inc. and Industry Property LLC EX-10.1 2 ex10-1.htm Exhibit 10.1 N o r t h T e x a s C o m m e r c i a l A s s o c i a t i o n o f R e a l t o r s ® C O M M E R C I A L L E A S E A G R E E M E N T between Industrial Property LLC (Landlord) and Todos Medical U.S.A. (Tenant) TABLE OF CONTENTS Article 1. Defined Terms 2 2. Lease and Term 8 3. Rent and Security Deposit 9 4. Taxes 10 5. Insurance and Indemnity 11 6. Use of Premises
August 22, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ?June 30, 2022 For the three months ended ?June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm
August 22, 2022	EX-10.63	Secured Loan Agreement dated July 19, 2021, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.63
August 22, 2022	EX-10.66	Loan Agreement dated June 15, 2022, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. EX-10.66 46 ex10-66.htm Exhibit 10.66
August 22, 2022	EX-10.65	Amended and Restated Secured Convertible Promissory Note dated February 18, 2022, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. EX-10.65 41 ex10-65.htm Exhibit 10.65
August 22, 2022	EX-10.64	Secured Promissory Note dated July 19, 2021, between the Company and Friends of Yeshiva Orot Hateshuva, Inc. Exhibit 10.64
August 22, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St
August 22, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
August 22, 2022	EX-10.62	Secured Convertible Note entered into as of May 20, 2022, between the Company and Leviston Resources, LLC Exhibit 10.62
August 15, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ?
August 12, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St
August 10, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Todos Medical Ltd.
August 5, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 Todos Medical Ltd.
July 28, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Todos Medical Ltd.
July 28, 2022	S-1	As filed with the Securities and Exchange Commission on July 27, 2022 As filed with the Securities and Exchange Commission on July 27, 2022 Registration No.
May 16, 2022	EX-10.59	Revolving Line of Credit Agreement by and between Todos Medical Ltd. and Provista Diagnostics Inc. and Testing 123, LLC, dated as of March 14, 2022 (filed as Exhibit 10.59 to the Company’s quarterly report on Form 10-Q, filed with the SEC on May 16, 2022). EX-10.59 2 ex10-59.htm Exhibit 10-59
May 16, 2022	EX-10.61	Revolving Credit Note, dated March 14, 2022, from Todos Medical Ltd. and Provista Diagnostics Inc. to Testing 123 LLC (filed as Exhibit 10.61 to the Company’s quarterly report on Form 10-Q, filed with the SEC on May 16, 2022). Exhibit 10.61
May 16, 2022	EX-10.60	Pledge and Security Agreement made and entered into on March 14, 2022, by and between Todos Medical Ltd. and Provista Diagnostics Inc, and Testing 123 LLC (filed as Exhibit 10.60 to the Company’s quarterly report on Form 10-Q, filed with the SEC on May 16, 2022). Exhibit 10.60
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 For the three months ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm
April 6, 2022	SC 13G	TOMDF / Todos Med Ltd (Israel) / Leviston Resources Llc - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
April 1, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Todos Medical Ltd.
April 1, 2022	EX-99.1	Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates Exhibit 99.1 Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates New York, NY, and Tel Aviv, ISRAEL ? April 1, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and provided corporate updates. ?2021 was
March 31, 2022	EX-10.31	Medical Device Contract Manufacturing Agreement, dated June 4, 2020 between Todos Medical USA, Inc. and 3D Biomedicine Science and Technology Co. Ltd. filed as Exhibit 10.31 on the Company’s Annual Report on Form 10-K, filed on March 31, 2022. EX-10.31 9 ex10-31.htm Exhibit 10.31
March 31, 2022	EX-4.2	Todos Medical Ltd. 2021 Equity Incentive Plan Exhibit 4.2 TODOS MEDICAL LTD. 2021 EQUITY INCENTIVE PLAN 1. PURPOSE The purpose of this Equity Incentive Plan is to secure for Todos Medical Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers, directors, service providers and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company’s future g
March 31, 2022	EX-10.27	Amendment to Receivables Financing Agreement effective as of November 19, 2020 by and among Toledo Advisors L.L.C., Corona Diagnostics LLC, Todos Medical USA, a Nevada corporation and Todos Medical Ltd. EX-10.27 5 ex10-27.htm Exhibit 10.27
March 31, 2022	EX-10.30	Medical Device Distribution Agreement, dated June 4, 2020 between Todos Medical USA, Inc. and 3D Biomedicine Science and Technology Co. Ltd. filed as Exhibit 10.30 on the Company’s Annual Report on Form 10-K, filed on March 31, 2022. EX-10.30 8 ex10-30.htm Exhibit 10.30
March 31, 2022	EX-4.3	Description of Ordinary Shares EX-4.3 3 ex4-3.htm EXHIBIT 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value NIS 0.0001 per share, of Todos Medical Ltd. (the “Company,” “we” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This descript
March 31, 2022	EX-10.33	Distribution Agreement, dated July 23, 2020, between Todos Medical Ltd. and PCL Inc. Exhibit 10.33 Distribution Agreement This Distribution Agreement (the “Agreement”) is made and entered into on this 22th day of July, 2020 (the “Effective Date”) by and between TODOS Medical USA, Inc., a company registered under the laws of the state of Nevada in the United States, with its principal address of business located at 45 Wall Street, Suite 920, New York, NY 10005 (hereinafter referred
March 31, 2022	EX-10.34	Amendment No. 1, dated July 28, 2020, to the Binding Joint Venture Agreement between Todos Medical Ltd. and Amarantus Bioscience Holdings, Inc Exhibit 10.34 AMENDMENT NO.1 TO BINDING JOINT VENTURE AGREEMENT This AMENDMENT NO. 1 (the “Amendment”) to the BINDING JOINT VENTURE AGREEMENT (the “Agreement”) originally entered into as of November 24, 2018, by and between Amarantus Bioscience Holdings, Inc. (“Amarantus”) and Todos Medical, Ltd., an Israel corporation (“Todos” or the “Company”) is made effective as of July , 2020. Capitalized ter
March 31, 2022	EX-10.29	Secured Convertible Equipment Loan Agreement, dated December 31, 2020, between Todos Medical Ltd. and Harper Advance LLC. EX-10.29 7 ex10-29.htm Exhibit 10.29 .
March 31, 2022	EX-21.1	List of Subsidiaries EX-21.1 13 ex21-1.htm Exhibit 21.1 TODOS MEDICAL LTD. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Todos Medical USA Nevada Todos Medical Singapore Pte. Ltd. Singapore Corona Diagnostics LLC (a subsidiary of Todos Medical USA) Nevada Breakthrough Diagnostics Inc. Nevada Provista Diagnostics, Inc. Delaware
March 31, 2022	EX-10.28	Secured Convertible Equipment Loan Agreement, dated November 4, 2020, between Todos Medical Ltd. and Friends of Yeshiva Orot Hateshuva Inc EX-10.28 6 ex10-28.htm Exhibit 10.28
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-56026 TODOS MEDICAL LTD.
March 31, 2022	EX-10.26	Receivables Financing Agreement effective as of June 19, 2020 by and among Toledo Advisors L.L.C., Corona Diagnostics LLC, Todos Medical USA, a Nevada corporation and Todos Medical Ltd. filed as Exhibit 10.26 on the Company’s Annual Report on Form 10-K, filed on March 31, 2022. EX-10.26 4 ex10-26.htm Exhibit 10.26 RECEIVABLES FINANCING AGREEMENT dated as of June 19, 2020 among Corona Diagnostics LLC, Todos Medical USA and Todos Medical Ltd., As Borrower, and Toledo Advisors L.L.C., As Lender RECEIVABLES FINANCING AGREEMENT This Receivables Financing Agreement (as amended, restated, supplemented or otherwise modified, this “Agreement”) is entered into between Toledo Advis
March 31, 2022	EX-10.32	Distribution Agreement dated June 18, 2020 between Todos Medical Ltd. and Meridian Health Services Network, Inc. Exhibit 10.32
March 17, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Todos Medical Ltd.
March 17, 2022	EX-10.1	Share Purchase Agreement, dated March 11, 2022, among the Company, 3CL Sciences Ltd., an Israeli corporation, and NLC Pharma Ltd., an Israeli corporation, filed as Exhibit 10.1 on the Company’s Report on Form 8-K filed on March 16, 2022 Exhibit 10.1
March 17, 2022	EX-99.1	Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma - Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Exhibit 99.1 Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma - Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir?, Tollovid?, Tollovid Daily? and TolloTest? for COVID-19 - - Positions Todos Medical as the leader of oral antivirals for hospitalized COVID-19 patients to sp
February 7, 2022	424B4	TODOS MEDICAL LTD. 261,067,037 Ordinary Shares 424B4 1 form424b4.htm Filed pursuant to Rule 424(b)(4) Registration No. 333-256053 Prospectus TODOS MEDICAL LTD. 261,067,037 Ordinary Shares This prospectus relates to the resale by the selling shareholders named herein, from time to time, of up to (i) 123,086,088 ordinary shares, (the “Convertible Note Shares”), issuable upon the exercise of outstanding convertible notes (the “Convertible Notes”)
February 3, 2022	CORRESP	February 3, 2022 CORRESP 1 filename1.htm February 3, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Todos Medical Ltd. (the “Company”) Registration Statement on Form S-1/A File No. 333-256053 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the
February 2, 2022	S-1/A	As filed with the Securities and Exchange Commission on February 2, 2022 As filed with the Securities and Exchange Commission on February 2, 2022 Registration No.
January 18, 2022	S-1/A	Power of Attorney (included on signature page to registration statement). Registration No. 333-256053 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Todos Medical Ltd. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) 2835 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identi
November 29, 2021	EX-10.3	Form of Convertible Promissory Note EX-10.3 4 ex10-3.htm Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGIST
November 29, 2021	EX-10.1	Form of License Agreement EX-10.1 2 ex10-1.htm Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT THIS LICENSE AGREEMENT is made and entered into as of November 1, 2021, (the “Effective Date”) by and between Todos Medical Ltd.’s (“TOMDF”) wholly-owned subsidiary 3CL Scie
November 29, 2021	EX-10.4	Binding Letter of Intent dated as of November 24, 2021 Exhibit 10.4 Project 3CL [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. BINDING LETTER OF INTENT (“LOI”) Asset Purchase from NLC Pharma The following is a summary of the principal terms by and between NLC Pharma, Ltd. (NLC) and Todos Medical Ltd. (Todos) (each a “Contract
November 29, 2021	EX-10.2	Securities Purchase Agreement EX-10.2 3 ex10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 11, 2021, between Todos Medical Ltd., a corporation organized under the laws of Israel (the “Company”), and T-Cell Protect Hellas S.A. (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2)
November 29, 2021	EX-99.1	Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma Exhibit 99.1 Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma ? Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL protease related IP ? Dr. Dorit Arad, pioneering biology researcher responsi
November 29, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 Todos Medical Ltd.
November 16, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Todos Medical Ltd.
November 16, 2021	EX-99.1	Todos Medical Reports Third Quarter 2021 Business and Financial Results Exhibit 99.1 Todos Medical Reports Third Quarter 2021 Business and Financial Results New York, NY, and Tel Aviv, ISRAEL ? November 15, 2021 - Todos Medical, Ltd. (?Todos Medical?) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the third quarter ended September 30, 2021. Corporate Highlights Integration of COVID-19 PCR automa
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 For the three months ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
November 1, 2021	SC 13G/A	TOMDF / Todos Med Ltd (Israel) / Strategic Investment Holdings, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) October 14, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th
October 22, 2021	EX-10.1	Securities Purchase Agreement dated October 21, 2021, between the Company and Kips Bay Select LP, filed as Exhibit 10.1 on the Company’s Report on Form 8-K filed on October 22, 2021 Exhibit 10.1
October 22, 2021	EX-10.3	Ordinary Shares Purchase Warrant dated October 21, 2021, issued by the Company to Kips Bay Select LP, filed as Exhibit 10.3 on the Company’s Report on Form 8-K filed on October 22, 2021. Exhibit 10.3
October 22, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 Todos Medical Ltd.
October 22, 2021	EX-10.2	Promissory Convertible Note dated October 21, 2021, issued by the Company to Kips Bay Select LP, filed as Exhibit 10.2 on the Company’s Report on Form 8-K filed on October 22, 2021. Exhibit 10.2
September 27, 2021	EX-99.1	Todos Medical Reports Second Quarter 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Todos Medical Reports Second Quarter 2021 Financial Results ■ Company recorded positive earnings of $0.01 per share as financial condition improved New York, NY, and Tel Aviv, ISRAEL – September 24, 2021 - Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for t
September 27, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2021 Todos Medical Ltd.
September 24, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 Todos Medical Ltd.
September 24, 2021	SC 13G	TOMDF / Todos Med Ltd (Israel) / Strategic Investment Holdings, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) August 19, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru
September 24, 2021	EX-10.1	Securities Purchase Agreement dated as of September 15, 2021, filed as Exhibit 10.1 on the Company’s Report on Form 8-K filed on September 24, 2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 15, 2021 (the ?Effective Date?), between Todos Medical Ltd., a corporation organized under the laws of Israel (the ?Company?), and (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act o
September 24, 2021	EX-10.3	Ordinary Shares Purchase Warrant dated September 15, 2021, filed as Exhibit 10.3 on the Company’s Report on Form 8-K filed on September 24, 2021. Exhibit 10.3 Exhibit B NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STAT
September 24, 2021	EX-10.2	Promissory Convertible Note dated September 15, 2021, filed as Exhibit 10.2 on the Company’s Report on Form 8-K filed on September 24, 2021. Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
September 24, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 For the three months ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis
September 15, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ea147491ex99-1todos.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares of Todos Medical Ltd., and that this Agr
September 15, 2021	SC 13G	TOMDF / Todos Med Ltd (Israel) / Geller Avi - SCHEDULE 13G Passive Investment SC 13G 1 ea147491-13gavitodos.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TODOS MEDICAL LTD. (Name of Issuer) ORDINARY SHARES OF NIS 0.01 PAR VALUE EACH (Title of Class of Securities) M8790Y108 (CUSIP Number) September 1, 2021 (Date of Event which Requires Filing of This Statement) Check the appropr
August 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition R
July 27, 2021	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 Todos Medical Ltd. (Exact name of registrant as specified in its charter) Israel 000-56026 n/a (State or other jurisdiction (Commission IRS Employer of i
July 8, 2021	EX-10.1	Securities Purchase Agreement dated as of July 7, 2021, filed as Exhibit 10.1 on the Company’s Report on Form 8-K filed on July 8, 2021. Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 7, 2021 (the ?Effective Date?), between Todos Medical Ltd., a corporation organized under the laws of Israel (the ?Company?), and Kips Bay Select LP (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section
July 8, 2021	EX-10.2	Promissory Convertible Note dated July 7, 2021, filed as Exhibit 10.2 on the Company’s Report on Form 8-K filed on July 8, 2021. Exhibit 10.2 Execution Version NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT
July 8, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 Todos Medical Ltd.
July 8, 2021	EX-10.3	Ordinary Shares Purchase Warrant dated July 7, 2021, filed as Exhibit 10.3 on the Company’s Report on Form 8-K filed on July 8, 2021. Exhibit 10.3 Exhibit B NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STAT
July 7, 2021	8-K/A	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Todos Medical Ltd.
July 6, 2021	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No.
July 6, 2021	EX-99.1	Provista Diagnostics, Inc. Exhibit 99.1 Provista Diagnostics, Inc. Financial Statements December 31, 2020 and 2019 CONTENTS INDEPENDENT AUDITORS? REPORT 1 - 2 FINANCIAL STATEMENTS Balance Sheets 3 Statements of Operations 4 Statements of Changes in Stockholder?s Equity 5 Statements of Cash Flows 5 - 6 Notes to Financial Statements 7 - 13 INDEPENDENT AUDITORS? REPORT Provista Diagnostics, Inc. Tel Aviv, Israel We have audite
July 6, 2021	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information gives effect to the agreement to purchase all of the outstanding shares of Provista Diagnostics Inc. (?Provista?), among Todos Medical Ltd. (?Todos Medical? or, the ?Company?) Provista, Strategic Investment Holdings, LLC (?SIH?), and Ascenda BioScienc
July 6, 2021	EX-99.2	Provista Diagnostics, Inc. Exhibit 99.2 Provista Diagnostics, Inc. Financial Statements As of March 31, 2021 and for the three months ended March 31, 2021 and 2020 CONTENTS FINANCIAL STATEMENTS Balance Sheet 1 Statements of Operations 2 Statements of Changes in Stockholder?s Equity 3 Statements of Cash Flows 4 Notes to Financial Statements 5 ? 10 PROVISTA DIAGNOSTICS, INC. BALANCE SHEET MARCH 31, 2021 2021 ASSETS CURRENT AS
June 30, 2021	EX-99.3	Notice and Access Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on July 26, 2021. Exhibit 99.3
June 30, 2021	EX-99.2	Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on July 26, 2021. Exhibit 99.2
June 30, 2021	8-K/A	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Todos Medical Ltd.
June 30, 2021	EX-99.1	TODOS MEDICAL LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2021 Exhibit 99.1 TODOS MEDICAL LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2021 To our Shareholders: You are cordially invited to attend the annual general meeting of shareholders (the ?Annual General Meeting? or the ?Meeting?), which will be held at the offices of Todos Medical, Ltd. (the ?Company? or ?Todos?), located at 121 Derech Menachem Begin, 30th Floor, Tel Avi
June 29, 2021	SC 13G	TOMDF / Todos Med Ltd (Israel) / Strategic Investment Holdings, LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) June 25, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate bo
June 28, 2021	EX-99.3	Notice and Access Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on July 26, 2021. Exhibit 99.3
June 28, 2021	EX-99.1	TODOS MEDICAL LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2021 Exhibits 99.1 TODOS MEDICAL LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2021 To our Shareholders: You are cordially invited to attend the annual general meeting of shareholders (the ?Annual General Meeting? or the ?Meeting?), which will be held at the offices of Todos Medical, Ltd. (the ?Company? or ?Todos?), located at 121 Derech Menachem Begin, 30th Floor, Tel Av
June 28, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Todos Medical Ltd.
June 28, 2021	EX-99.2	Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on July 26, 2021. Exhibit 99.2
June 25, 2021	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 Todos Medical Ltd.
June 25, 2021	EX-16.1	Letter from Fahn Kanne Grant Thornton to the U.S. Securities and Exchange Commission dated June 25, 2021 EXHIBIT 16.1 Fahn Kanne & Co. Grant Thornton Israel Tel Aviv Israel June 25, 2021 Office of the Chief Accountant U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Todos Medical Ltd. File No. 000-56026 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Todos Medical Ltd. dated June 23, 2021, and agree with the statements concerning our Firm contained therein. V
June 22, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 For the three months ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition
May 13, 2021	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Todos Medical Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Todos Medical Ltd. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) 2835 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) 121 Derech Me
May 7, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ________)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) May 4, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p
May 4, 2021	RW	- May 4, 2021 Via EDGAR Transmission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.
May 4, 2021	EX-99.1	Todos Medical Receives FDA Certificate of Free Sale for New 5 Day Tollovid™ Dosing Regimen EX-99.1 2 ex99-1.htm Exhibit 99.1 Todos Medical Receives FDA Certificate of Free Sale for New 5 Day Tollovid™ Dosing Regimen ● Company sees this new dosing regimen of 60 pills over 5 days as optimal for Tollovid, the Company’s 3CL protease inhibitor botanical dietary supplement that helps to support and maintain healthy immune function NEW YORK, NY, and REHOVAT, ISRAEL – May 4, 2021 - Todos Medica
May 4, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Todos Medical Ltd.
April 30, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Todos Medical Ltd.
April 30, 2021	EX-10.3	Ordinary Share Purchase Warrant dated April 2021, filed as Exhibit 10.3 on the Company’s Report on Form 8-K filed on April 30, 2021. Exhibit 10.3 ORDINARY SHARE PURCHASE WARRANT TODOS MEDICAL LTD. Warrant Shares: Initial Exercise Date: April, 2021 THIS ORDINARY SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Yozma Group Korea Co, Ltd. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th
April 30, 2021	EX-10.1	Securities Purchase Agreement dated as of April 27, 2021, filed as Exhibit 10.1 on the Company’s Report on Form 8-K filed on April 30,2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 27, 2021, between Todos Medical Ltd., a corporation organized under the laws of Israel (the ?Company?), and Yozma Global Genomic Fund 1 (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act
April 30, 2021	EX-10.2	Promissory Convertible Note dated April 2021, filed as Exhibit 10.2 on the Company’s Report on Form 8-K filed on April 30, 2021. Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
April 23, 2021	EX-10.4	Security Agreement dated April 19, 2021, filed as Exhibit 10.4 on the Company’s Form 8-K filed on April 23, 2021. Exhibit 10.4 SECURITY AGREEMENT THIS SECURITY AGREEMENT (?Agreement?), dated as of April 19, 2021, is made and entered into by and between Strategic Investment Holdings, LLC, a Nevada limited liability company (?SIH?), Ascenda BioSciences LLC, a Delaware limited liability company (?Ascenda? and together with SIH, the ?Secured Party?), and Provista Diagnostics, Inc., a Delaware corporation (the ?Pl
April 23, 2021	EX-10.3	Convertible Promissory Note dated April 19, 2021, filed as Exhibit 10.3 on the Company’s Form 8-K filed on April 23, 2021. Exhibit 10.3 CONVERTIBLE PROMISSORY NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
April 23, 2021	EX-10.2	Securities Purchase Agreement dated April 19, 2021, filed as Exhibit 10.2 on the Company’s Form 8-K filed on April 23, 2021. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?SPA?) is entered into by and between Todos Medical Ltd., an Israeli company (the ?Company?), and Strategic Investment Holdings, LLC, a Nevada limited liability company (the ?Holder? or ?Shareholder?) on the date set forth on the signature page hereto. WHEREAS, subject to the terms and conditions set forth in the A
April 23, 2021	EX-99.1	Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa® Breast Cancer Blood Test Exhibit 99.1 Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa? Breast Cancer Blood Test ? Todos plans to commercialize Videssa in late 2021 to reduce unnecessary biopsies in the $7.19 billion mammogram na?ve market and integrate it into its TBIA Platform ? Provista Diagnostics? testing lab in the Atlanta, Georgia area is currently performing COVID-19 testing, that will be au
April 23, 2021	EX-10.1	Agreement to Purchase Provista Diagnostics, Inc. dated April 19, 2021, filed as Exhibit 10.1 on the Company’s Form 8-K filed on April 23, 2021. Exhibit 10.1 AGREEMENT TO PURCHASE PROVISTA DIAGNOSTICS, INC. This Agreement (this ?Agreement?) is entered into by and between Todos Medical Ltd, a company formed under the laws of Israel (the ?Buyer?), Strategic Investment Holdings, LLC, a Nevada limited liability company (?Shareholder?), Ascenda BioSciences LLC, a Delaware limited liability company (?Ascenda?) and Provista Diagnostics, Inc., a D
April 23, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 Todos Medical Ltd.
April 21, 2021	EX-10.29	Loan Conversion Agreement dated May 10, 2020, by and among Todos Medical Ltd., Shmuel Mellman, Meir Ben Zur and Shay Zaga, filed as Exhibit 10.29 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.29
April 21, 2021	EX-10.35	Medical Device Distribution Agreement, dated June 4, 2020 between Todos Medical Ltd. and 3D Biomedicine Science and Technology Col. Ltd. filed as Exhibit 10.35 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.35
April 21, 2021	EX-10.33	Secured Convertible Equipment Loan Agreement, dated December 31, 2020, between Todos Medical Ltd. and Harper Advance LLC filed as Exhibit 10.33 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.33 .
April 21, 2021	EX-21.1	List of Subsidiaries (filed as Exhibit 21.1 to the Company’s annual report on Form 10-K, filed with the SEC on April 21, 2021). Exhibit 21.1 TODOS MEDICAL LTD. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Todos Medical USA Nevada Todos Medical Singapore Pte. Ltd. Singapore Corona Diagnostics LLC (a subsidiary of Todos Medical USA) Nevada Breakthrough Diagnostics Inc. Nevada
April 21, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-56026 TODOS MEDICAL
April 21, 2021	EX-1	EX-1 Exhibit 01
April 21, 2021	EX-10.34	Non-Exclusive Distribution Agreement, dated March 17, 2020 between Todos Medical Ltd. and 3D Biomedicine Science and Technology Col. Ltd. filed as Exhibit 10.34 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.34
April 21, 2021	EX-10.36	Distribution Agreement dated June 18, 2020 between Todos Medical Ltd. and Meridian Health Services Network, Inc. filed as Exhibit 10.36 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.36
April 21, 2021	EX-10.37	Distribution Agreement, dated July 23, 2020, between Todos Medical Ltd. and PCL Inc. filed as Exhibit 10.37 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.37 Distribution Agreement This Distribution Agreement (the ?Agreement?) is made and entered into on this 22th day of July, 2020 (the ?Effective Date?) by and between TODOS Medical USA, Inc., a company registered under the laws of the state of Nevada in the United States, with its principal address of business located at 45 Wall Street, Suite 920, New York, NY 10005 (hereinafter referred
April 21, 2021	EX-3	EX-3 Exhibit 03
April 21, 2021	EX-10.30	Receivables Financing Agreement effective as of June 19, 2020 by and among Toledo Advisors L.L.C., Corona Diagnostics LLC, Todos Medical USA, a Nevada corporation and Todos Medical Ltd. filed as Exhibit 10.30 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.30 RECEIVABLES FINANCING AGREEMENT dated as of June 19, 2020 among Corona Diagnostics LLC, Todos Medical USA and Todos Medical Ltd., As Borrower, and Toledo Advisors L.L.C., As Lender RECEIVABLES FINANCING AGREEMENT This Receivables Financing Agreement (as amended, restated, supplemented or otherwise modified, this ?Agreement?) is entered into between Toledo Advisors L.L.C., a Nevada li
April 21, 2021	EX-10.32	Secured Convertible Equipment Loan Agreement, dated November 4, 2020, between Todos Medical Ltd. and Friends of Yeshiva Orot Hateshuva Inc. filed as Exhibit 10.32 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.32
April 21, 2021	EX-10.31	Amendment to Receivables Financing Agreement effective as of November 19, 2020 by and among Toledo Advisors L.L.C., Corona Diagnostics LLC, Todos Medical USA, a Nevada corporation and Todos Medical Ltd. filed as Exhibit 10.31 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.31
April 21, 2021	EX-2	EX-2 Exhibit 02
April 21, 2021	EX-10.38	Amendment No. 1, dated July 28, 2020, to the Binding Joint Venture Agreement between Todos Medical Ltd. and Amarantus Bioscience Holdings, Inc. filed as Exhibit 10.38 on the Company’s Annual Report on Form 10-K, filed on April 21, 2021. Exhibit 10.38 AMENDMENT NO.1 TO BINDING JOINT VENTURE AGREEMENT This AMENDMENT NO. 1 (the ?Amendment?) to the BINDING JOINT VENTURE AGREEMENT (the ?Agreement?) originally entered into as of November 24, 2018, by and between Amarantus Bioscience Holdings, Inc. (?Amarantus?) and Todos Medical, Ltd., an Israel corporation (?Todos? or the ?Company?) is made effective as of July , 2020. Capitalized ter
April 15, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ________)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) April 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
April 14, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 Todos Medical Ltd.
April 14, 2021	EX-10.2	Form of Promissory Convertible Note issued by Todos Medical Ltd. to the Purchaser, filed as Exhibit 10.2 on the Company’s Form 8-K filed April 14, 2021. Exhibit 10.2 Execution Version NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT
April 14, 2021	EX-10.3	Form of Ordinary Share Purchase Warrant issued by Todos Medical Ltd. to the Purchaser, filed as Exhibit 10.3 on the Company’s Form 8-K filed on April 14, 2021. Exhibit 10.3 Execution Version ORDINARY SHARE PURCHASE WARRANT TODOS MEDICAL LTD. Warrant Shares: 16,000,000 Initial Exercise Date: April 8, 2021 THIS ORDINARY SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte
April 14, 2021	EX-10.1	Form of Securities Purchase Agreement, dated April 8, 2021, between Todos Medical Ltd. and the Purchaser, filed as Exhibit 10.1 on the Company’s Form 8-K filed April 14, 2021. Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 8, 2021 (the ?Effective Date?), between Todos Medical Ltd., a corporation organized under the laws of Israel (the ?Company?), and (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Sec
April 1, 2021	NT 10-K	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING [X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transit
March 22, 2021	EX-10.1	Waiver Agreement. Exhibit 10.1 Waiver Agreement Pursuant to Section 5.5 of the Securities Purchase Agreement (the ?Agreement?) dated January 22, 2021 between Todos Medical Ltd. and Yozma Global Genomic Fund 1 (?Yozma?), Yozma hereby waives Section 4.22 of the Agreement in perpetuity and agrees that it will not be entitled to designate anyone as its Board designee. Capitalized terms not defined herein shall have the
March 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2021 Todos Medical Ltd.
March 12, 2021	EX-10.1	Form of Closing Agreement between Todos Medical Ltd. and the purchaser named therein, a form of which is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated March 10, 2021, and incorporated herein by reference. Exhibit 10.1 CLOSING AGREEMENT This Closing Agreement (this ?Closing Agreement?) is dated as of March [], 2021 (the ?Effective Date?), by and between Todos Medical Ltd., a company organized and existing under the laws of Israel (the ?Company?) and Leviston Resources LLC, a Delaware limited liability company (?Purchaser?). Each of the Company and Purchaser are collectively referred to herein as the
March 12, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 Todos Medical Ltd.
February 5, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ____)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 (Title of Class of Securities) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 26, 2021	EX-10.3	Form of Ordinary Share Purchase Warrant issued by Todos Medical Ltd. to Yozma Korea Group Ltd., filed as Exhibit 10.3 on the Company’s Form 8-K filed on January 26, 2021. Exhibit 10.3 ORDINARY SHARE PURCHASE WARRANT TODOS MEDICAL LTD. Warrant Shares: 16,956,929 Initial Exercise Date: January, 2021 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Yozma Group Korea Co, Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
January 26, 2021	EX-10.1	Securities Purchase Agreement dated as of January 22, 2021, between Todos Medical Ltd and Yozma Global Genomic Fund 1, filed as Exhibit 10.1 on the Company’s Form 8-K filed January 26, 2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 22 , 2021, between Todos Medical Ltd., a corporation organized under the laws of Israel (the “Company”), and Yozma Global Genomic Fund 1 (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities A
January 26, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 Todos Medical Ltd.
January 26, 2021	EX-10.2	Form of Promissory Convertible Note issued by Todos Medical Ltd to Yozma Global Genomic Fund 1, filed as Exhibit 10.2 on the Company’s Form 8-K filed January 26, 2021. Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
January 26, 2021	EX-99.1	Todos Medical Announces Strategic Investment by Yozma Group Korea Exhibit 99.1 Todos Medical Announces Strategic Investment by Yozma Group Korea NEW YORK, NY, REHOVAT, ISRAEL, SOUTH KOREA, Jan. 25, 2021 (GLOBE NEWSWIRE) —Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced
December 15, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of
December 15, 2020	EX-99.1	Company Presentation Exhibit 99.1
August 20, 2020	424B4	TODOS MEDICAL LTD. 50,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(4) Registration Number 333-244414 Prospectus TODOS MEDICAL LTD.
August 17, 2020	EX-10.8	Exclusive option agreement among the Company, Strategic Investment Holdings, LLC, Ascenda BioSciences LLC and Provista Diagnostics, Inc. dated January 6, 2020. filed as Exhibit 10.8 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.8
August 17, 2020	EX-10.22	Loan Agreement dated March 23, 2020 by and between Todos Medical Ltd. and Bel Har Investments Ltd., filed as Exhibit 10.22 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.22
August 17, 2020	EX-10.27	Form of Loan Agreement dated March 24, 2020 by and between Todos Medical Ltd. and Tehresa Yee Ling Tan, filed as Exhibit 10.27 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.27
August 17, 2020	EX-10.20	Loan Agreement dated February 25, 2020 by and between Todos Medical Ltd. and Ethel Zelniec, filed as Exhibit 10.20 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.20
August 17, 2020	EX-10.28	Loan Agreement dated January 27, 2020 by and between Todos Medical Ltd. and Greentree Financial Group Inc., filed as Exhibit 10.28 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.28
August 17, 2020	EX-10.13	Form of convertible note dated July 28, 2020, between the Company and the Todos Investors. filed as Exhibit 10.13 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.13
August 17, 2020	EX-10.11	Securities Purchase Agreement with Alexsander Shmuel Bar On, dated June 29, 2020. filed as Exhibit 10.11 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020 Exhibit 10.11
August 17, 2020	EX-10.9	2% Convertible Redeemable Note made by the Company in favor of Shmuel Rotbard in the original principal amount of $375,000 dated June 15, 2020. filed as Exhibit 10.9 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.9
August 17, 2020	F-1/A	- As filed with the Securities and Exchange Commission on August 17, 2020 Registration No.
August 17, 2020	EX-10.25	Loan Agreement dated March 15, 2020 by and between Todos Medical Ltd. and Shmuel Rotbard, filed as Exhibit 10.25 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.25
August 17, 2020	EX-10.24	Loan Agreement dated March 22, 2020 by and between Todos Medical Ltd. and Avner Krohn, filed as Exhibit 10.24 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.24
August 17, 2020	CORRESP	- August 17, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F.
August 17, 2020	EX-10.26	Form of Loan Agreement dated March 24, 2020 by and between Todos Medical Ltd. and DPH Investments Ltd., filed as Exhibit 10.26 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.26
August 17, 2020	EX-10.10	Securities Purchase Agreement with Daniel Reich, dated June 23, 2020. filed as Exhibit 10.10 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.10
August 17, 2020	EX-21.1	List of Subsidiaries Exhibit 21.1 TODOS MEDICAL LTD. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Todos Medical USA Nevada Todos Medical Singapore Pte. Ltd. Singapore
August 17, 2020	EX-10.12	Securities Purchase Agreement, dated July 9, 2020, with Leviston Resources, LLC. filed as Exhibit 10.12 to the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.12
August 17, 2020	EX-10.23	Loan Agreement dated March 24, 2020 by and between Todos Medical Ltd. and DPH Investments Ltd., filed as Exhibit 10.23 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.23
August 17, 2020	EX-10.19	Loan Agreement dated March 24, 2020 by and between Todos Medical Ltd. and Ethel Zelniec, filed as Exhibit 10.19 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.19 LOAN AGREEMENT This Loan Agreement (?Agreement?) is made and entered into in this 24th day of March, 2020 (?Effective Date?), by and between Todos Medical Ltd., an Israel corporation, its successors and assigns (the ?Company?), and Ethel Zelniec (?Lender?). RECITALS WHEREAS, the Company is in need of capital for working capital and inventory and Lender has agreed to provide up to $10
August 17, 2020	EX-10.21	Loan Agreement dated January 23, 2020, by and between Todos Medical Ltd. and Bel Har Investments Ltd., filed as Exhibit 10.21 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.21
August 13, 2020	EX-10.8	Exclusive option agreement among the Company, Strategic Investment Holdings, LLC, Ascenda BioSciences LLC and Provista Diagnostics, Inc. dated January 6, 2020.
August 13, 2020	EX-10.12	Securities Purchase Agreement, dated July 9, 2020, with Leviston Resources, LLC.
August 13, 2020	EX-10.9	2% Convertible Redeemable Note made by the Company in favor of Shmuel Rotbard in the original principal amount of $375,000 dated June 15, 2020.
August 13, 2020	EX-10.10	Securities Purchase Agreement with Daniel Reich, dated June 23, 2020.
August 13, 2020	EX-10.13	Form of convertible note dated July 28, 2020, between the Company and the Todos Investors.
August 13, 2020	F-1	- As filed with the Securities and Exchange Commission on August 13, 2020 Registration No.
August 13, 2020	EX-10.19	Loan Agreement dated March 24, 2020 by and between Todos Medical Ltd. and Ethel Zelniec, filed as Exhibit 10.19 on the Company’s Registration Statement on Form F-1/A, filed on August 17, 2020. Exhibit 10.19
August 13, 2020	EX-10.11	Securities Purchase Agreement with Alexsander Shmuel Bar On, dated June 29, 2020.
August 12, 2020	F-1/A	- As filed with the Securities and Exchange Commission on August 12, 2020 Registration No.
August 11, 2020	F-1	- As filed with the Securities and Exchange Commission on August 11, 2020 Registration No.
August 6, 2020	EX-12.1	Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 furnished herewith. Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gerald Commissiong, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of Todos Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to stat
August 6, 2020	EX-10.1	Purchase Agreement dated as of August 4, 2020 by and between Todos Medical Ltd. and Lincoln Park Capital Fund, LLC. filed as Exhibit 10.1 to the Company’s Form 6-K filed on August 6, 2020. Exhibit 10.1 Execution Version PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of August 4, 2020, by and between TODOS MEDICAL LTD., a State of Israel corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the In
August 6, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of P
August 6, 2020	EX-10.2	Registration Rights Agreement dated as of August 4, 2020 by and between Todos Medical Ltd. and Lincoln Park Capital Fund, LLC, filed as Exhibit 10.2 to the Company’s Form 6-K filed on August 6, 2020. Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 4, 2020, by and between TODOS MEDICAL LTD., a State of Israel corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise define
August 6, 2020	EX-12.2	Certification of the Principal Financial and Accounting Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 furnished herewith. Exhibit 12.2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Daniel Hirsch, certify that: 1. I have reviewed this Annual Report on Form 20-F/A of Todos Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m
August 6, 2020	EX-13.1	Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith. Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Todos Medical Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (t
August 6, 2020	20-F/A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A (Amendment No.
July 31, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pri
July 28, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pri
July 15, 2020	SC 13D	TOMDF / Todos Med Ltd (Israel) / Strategic Investment Holdings, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) Mr. Norberto P?rez O?Neill The Strategic Group, LLC 875 Carretera 693, suite 201 Dorado, PR 00646 Tel: (787) 626-6500
July 13, 2020	EX-99.2	Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on July 29, 2020. Exhibit 99.2
July 13, 2020	EX-99.1	TODOS MEDICAL LTD. NOTICEOFANNUALGENERALMEETINGOFSHAREHOLDERS TO BE HELD ON July 29, 2020 Exhibit 99.1 TODOS MEDICAL LTD. NOTICEOFANNUALGENERALMEETINGOFSHAREHOLDERS TO BE HELD ON July 29, 2020 To Our Shareholders: You are cordially invited to attend the Annual General Meeting of the Shareholders of Todos Medical Ltd., an Israeli corporation, (“Todos” or the “Company”), which will be held on Wednesday, July 29, 2020, at 10:00 a.m. local time, at the offices of Todos Medical Ltd., 1 HaMa
July 13, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pri
July 2, 2020	RW	- July 2, 2020 Via EDGAR Transmission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.
June 29, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pri
June 15, 2020	EX-1.3	Charter of the Compensation Committee of the Board of Directors Exhibit 1.3 TODOS MEDICAL LTD. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS I. PURPOSE The Compensation Committee (the “Committee”) of the Board of Board of Directors (the “Board”) of Todos Medical Ltd. (the “Company”) is appointed by the Board of the Company to assist the Board in performing its responsibilities relating to compensation and benefits of the Company’s officers an
June 15, 2020	EX-4.12	2% Convertible Redeemable Note made by the Company in favor of Shmuel Rotbard in the original principal amount of $375,000 dated June 15, 2020. Exhibit 4.12 THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATIONS UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”). ACCORDINGLY, NONE OF THE SECURITIES TO WHICH THIS CERTIFICATE RELATES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE 1933 ACT,
June 15, 2020	EX-4.11	Exclusive option agreement among the Company, Strategic Investment Holdings, LLC, Ascenda BioSciences LLC and Provista Diagnostics, Inc. dated January 6, 2020. Exhibit 4.11
June 15, 2020	EX-12.1	Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 furnished herewith. Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gerald Commissiong, certify that: 1. I have reviewed this Annual Report on Form 20-F of Todos Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state
June 15, 2020	EX-1.2	Charter of the Audit Committee of the Board of Directors Exhibit 1.3 TODOS MEDICAL LTD. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS I. PURPOSE 1.1 The Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Todos Medical Ltd. (the “Company”) is appointed by the Board of the Company to oversee the accounting and financial reporting processes and the audits of the Company’s financial statements. In this regard, the Commit
June 15, 2020	20-F	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No.
June 15, 2020	EX-12.2	Certification of the Principal Financial and Accounting Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 furnished herewith. Exhibit 12.2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Daniel Hirsch, certify that: 1. I have reviewed this Annual Report on Form 20-F of Todos Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat
June 15, 2020	EX-13.1	Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith. Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Todos Medical Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (t
May 18, 2020	EX-99.1	Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests Exhibit 99.1 Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests ● Sub-distributor has network of state and local government clients seeking testing solutions ● Return to Church program being initiated in Orlando, Florida. area REHOVOT, Israel, SINGAPORE and NEW YORK (May 18, 2020) – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution
May 18, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Prin
May 11, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Prin
May 8, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Prin
May 8, 2020	EX-99.2	Exchange Agreement dated April 13, 2020. Exhibit 99.2
May 8, 2020	EX-99.1	Amended and Restated Collaboration Agreement between Todos Medical USA, Inc. and Emerald Organic Products, Inc. dated April 24, 2020 Exhibit 99.1
May 8, 2020	EX-99.1	May 1, 2020 Exhibit 99.1 May 1, 2020 Toledo Advisors, LLC Attn: Moshe Mueller Re: Todos Medical Ltd. (the “Company”) Dear Moshe: This letter agreement hereby confirms that the conversion price of the aggregate principal amount of Notes of the Company of $119,295.70 plus $2,844.82 of accrued interest owned by Toledo Advisors, LLC (“Toledo”) is hereby reduced to $0.02 per share and the Company will issue 6,107,
May 8, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Prin
April 28, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pr
April 28, 2020	EX-99.1	Todos Medical Announces Positive Data for Serology Point-of-Care Fingerprick Antibody Test Kits Exhibit 99.1 Todos Medical Announces Positive Data for Serology Point-of-Care Fingerprick Antibody Test Kits REHOVOT, Israel, SINGAPORE and NEW YORK (April 28, 2020) – Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests f
April 21, 2020	EX-99.1	Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits Exhibit 99.1 Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits ? Gibraltar Brothers & Associates, LLC has entered into agreements with Gnomegen, LLC to supply Todos with its proprietary Real Time digital PCR Test Kits for COVID-19 REHOVOT, Israel, SINGAPORE and NEW YORK (April 21, 2020) ? Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro
April 21, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pr
April 17, 2020	EX-99.1	Todos Medical Provides Corporate Update Exhibit 99.1 Todos Medical Provides Corporate Update ? Corona Diagnostics JV adds COVID-19 EUA-submitted point-of-care antibody test kit suppliers ? Ongoing pre-commercial clinical trial for TMB-1 and TMB-2 progressing despite COVID-19 ? Full acquisition of Breakthrough Diagnostics JV pending completion of independent valuation ? Acquisition of Provista Diagnostics and related Nasdaq listing remai
April 17, 2020	EX-99.2	Todos Medical Achieves Medical Importer Status with US FDA Exhibit 99.2 Todos Medical Achieves Medical Importer Status with US FDA REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 15, 2020 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - Todos Medical Ltd. (TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that the United States Food & Drug
April 17, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of Pr
April 17, 2020	EX-99.3	Todos Medical Appoints Dr. Lauren Chung to its Board of Directors Exhibit 99.3 Todos Medical Appoints Dr. Lauren Chung to its Board of Directors ? Receives valuation of Alzheimer?s disease blood diagnostic LymPro Test ? Retains Donohoe Advisors to assist with Nasdaq CM? listing process REHOVOT, Israel, SINGAPORE and NEW YORK (April 17, 2020) ? Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests f
April 14, 2020	EX-99.1	TODOS MEDICAL LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 11, 2020 Exhibit 99.1 TODOS MEDICAL LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 11, 2020 To Our Shareholders: You are cordially invited to attend the Extraordinary General Meeting of the Shareholders (the ?Meeting?) of Todos Medical Ltd., an Israeli corporation, (?Todos? or the ?Company?), which will be held on May 11, 2020, at 4:00 p.m. local time, at the offices of Todo
April 14, 2020	EX-99.2	Proxy Card for the Extraordinary General Meeting of Shareholders of the Company to be held on May 11, 2020 Exhibit 99.2
April 14, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 7670301 Tel: (011) (972) 8-633-3964 (Address of Pr
April 10, 2020	SC 13G	Passive Investment - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) April 1, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
April 7, 2020	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 333-20974 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of P
March 31, 2020	EX-99.2	Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar Exhibit 99.2 Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar ? Colloidal Gold demonstrated 90.4% sensitivity and 100% specificity in Chinese clinical trial ? Provides results in two to 10 minutes at the point of care using blood from a finger prick
March 31, 2020	EX-99.4	Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar Exhibit 99.4 Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar ? Todos expands rights to include Asian countries and to include PCR test kits ? Corona Diagnostics JV with Emerald Organic responsible for commercialization ? Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effort REHOVOT, Israel and New York, N
March 31, 2020	EX-99.3	Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits Exhibit 99.3 Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits Emerald Organic has formed Corona Diagnostics, LLC in coordination with Todos Medical to bringing all efforts to bear to address the COVID-19 screening and testing shortage across the United States. HOLBROO
March 31, 2020	EX-99.1	Todos Medical Enters Into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement With 3D BioMed Exhibit 99.1 Todos Medical Enters Into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement With 3D BioMed ? 3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial ? Nucleic Acid test performed on proprietary automated platform to increase throughput ? CE Mark and Chinese FDA approval have been received; 3D BioMed in discussions with US FDA ? Tec
March 31, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant’s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of P
February 28, 2020	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2020 Commission File Number 000-56026 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of
February 28, 2020	EX-99.1	Todos Medical Announces Legacy Convertible Note Extension, Lock-Up Agreements, and New Debt Financing Exhibit 99.1 Todos Medical Announces Legacy Convertible Note Extension, Lock-Up Agreements, and New Debt Financing February 25, 2020 at 8:00 AM EST REHOVOT, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) ? Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announ
February 21, 2020	SC 13G	Passive Investment - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Todos Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M8790Y108 (CUSIP Number) January 21, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r
January 10, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant's name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of
January 6, 2020	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission File Number 333-209 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant's name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of
January 6, 2020	6-K/A	Current Report of Foreign Issuer - AMENDMENT NO. 1 TO REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant's name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-6
January 3, 2020	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address o
October 7, 2019	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 Commission File Number 333-209744 TODOS MEDICAL LTD. (Translation of registrant?s name into English) 1 Hamada Street Rehovot, Israel 2244427 Tel: (011) (972) 8-633-3964 (Address of
September 24, 2019	F-1/A	- AMENDMENT NO. 6 TO FORM F-1 As filed with the Securities and Exchange Commission on September 24, 2019 Registration No.
September 23, 2019	F-1/A	As filed with the Securities and Exchange Commission on September 23, 2019 As filed with the Securities and Exchange Commission on September 23, 2019 Registration No.
September 4, 2019	F-1/A	- AMENDMENT NO. 4 TO FORM F-1 As filed with the Securities and Exchange Commission on September 4, 2019 Registration No.

TOMDF / Todos Medical Ltd. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)